Why the study?
Although clopidogrel reduces thromboembolic complications in endovascular treatment of intracranial aneurysms, clopidogrel-resistant patients still experience ischemic adverse events, prompting comparison with ticagrelor.
Does ticagrelor prevent thrombotic and ischemic complications compared to clopidogrel in patients undergoing endovascular intervention for intracranial aneurysms?
Does ticagrelor prevent thrombotic and ischemic complications compared to clopidogrel in patients undergoing endovascular intervention for intracranial aneurysms?
Ticagrelor is an effective and safe alternative to clopidogrel for preventing thromboembolic complications in patients undergoing endovascular intervention for intracranial aneurysms, particularly in those with clopidogrel resistance.
No takes yet. Share an insight, caveat, or question.
Ticagrelor provides a viable alternative for clopidogrel-resistant patients; extends meta-analytic support for tailored DAPT in neuroendovascular procedures.
Xia et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: